Lakefront Biotherapeutics NV current report, Q4 FY2016

Business Context and Reporting Period

This Form 6-K filing is submitted by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in the metadata request) for the month of December 2016. The registrant is a foreign private issuer incorporated in Belgium. The filing primarily serves to incorporate by reference a press release dated December 20, 2016, regarding a material event.

Financial Metrics

The filing text does not provide specific financial data. There are no reported values for revenue, profit, cash flow, margins, debt, or liquidity within this document.

Material Changes

The document does not detail financial changes versus prior periods. The material event disclosed is the issuance of a press release on December 20, 2016, the content of which is attached as Exhibit 99.1 but not summarized in the body of this filing.

Guidance, Outlook, and Risks

The filing does not contain management commentary, financial guidance, or specific risk factors. It notes that the press release (Exhibit 99.1) is incorporated by reference into the Company's Registration Statements on Forms F-3 and S-8, with the exception of specific quotes from Prof. Jane Davies and Dr. Piet Wigerinck.

Key Facts for Investor Verification

  • Verify the actual content of the press release dated December 20, 2016 (Exhibit 99.1), as the filing itself contains no operational details.
  • Confirm the registrant is Galapagos NV, not Lakefront Biotherapeutics NV.
  • Note that specific quotes from Prof. Jane Davies and Dr. Piet Wigerinck in the press release are excluded from incorporation by reference into the Company's registration statements.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.